Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK closes £574m sale of Aspen stock

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline has completed the sale of 28.2 million shares in Aspen Pharmacare, raising £574m and reducing its stake from around 12.4% to 6.2% in the South African firm. It will cease accounting for Aspen as an associate, but has undertaken not to dispose of any shares in Aspen for the next 180 days. The proceeds of the sale, details of which were announced on 12 March, will give GSK greater financial flexibility to invest in core franchises and the assets it has gained with its multi-faceted transaction with Novartis.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts